Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDialysis/Renal ReplacementAetna hemodialysis schizophrenia Coverage Update |…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0291

    Hemodialysis for Schizophrenia

    Customize your policy alerts

    Sign up for Aetna Policy 0291 alerts

    Get alerted when Policy 0291 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs the use of hemodialysis as a treatment for schizophrenia and is intended for providers and payers determining coverage for this indication.

    Policy Summary
    PayerAetna
    PolicyHemodialysis for Schizophrenia
    Policy CodePolicy 0291
    Change TypeNo material change
    Effective DateOct 13, 1998
    Last ReviewMay 5, 2023
    Next Review DateMar 14, 2024
    Key ActionDo not authorize hemodialysis for the treatment of schizophrenia because it is considered experimental and investigational.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    experimentalcoverage stance
    90935,90937example CPT codes
    F20.0-F20.9ICD-10 refs
    9 trials

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    trials summarized
    23%AE rate

    Coverage Determination

    Experimental / Investigational — Coverage statement

    Covered when ALL of the following are met:

    Experimental and investigational statement: Hemodialysis for the treatment of schizophrenia is considered experimental and investigational because the effectiveness of this approach has not been demonstrated and established.

    Based on lack of demonstrated efficacy in sham-controlled trials and systematic review evidence.

    Use of hemodialysis specifically to treat schizophrenia is excluded from coverage as experimental and investigational. The policy states that "Hemodialysis for the treatment of schizophrenia is considered experimental and investigational because the effectiveness of this approach has not been demonstrated and established." In addition, the Medicare National Coverage Determination similarly finds the evidence inconclusive and does not cover hemodialysis for the treatment of schizophrenia.

    Hemodialysis for schizophrenia is considered not medically necessary because randomized, sham-controlled trials and a systematic review found no consistent therapeutic benefit. Multiple well-designed sham-controlled trials failed to show a significant effect on schizophrenia symptoms, and a systematic review identified 9 randomized, double-blinded trials (total n = 105) with mostly negative results; adverse events were reported in 23% of patients. Given the lack of demonstrated efficacy and the occurrence of harms, hemodialysis is not supported as a treatment for schizophrenia.

    Relevant Codes

    CPT Codes referencedCPT
    90935Hemodialysis procedure with single physician evaluation.
    90937Hemodialysis procedure requiring repeated evaluation(s) with or without substantial revision of dialysis prescription.
    ICD-10 Codes referencedICD-10
    F20.0 - F20.9Schizophrenia
    ICD-10 Codes related to dialysisICD-10
    Z49.01 - Z49.32Encounter for care involving renal dialysis
    Z99.2Dependence on renal dialysis

    Provider Billing & Documentation Guidance

    Prior Authorization

    Prior authorization consideration for dialysis codes (90935, 90937)

    Hemodialysis procedure codes such as CPT 90935 and 90937 billed for the indication of schizophrenia are not supported by this policy because hemodialysis for schizophrenia is considered experimental and investigational and therefore is subject to prior authorization scrutiny and likely noncoverage.

    • CPT 90935 — Hemodialysis procedure with single physician evaluation.
    • CPT 90937 — Hemodialysis procedure requiring repeated evaluation(s) with or without substantial revision of dialysis prescription.
    Note

    Evidence does not support hemodialysis as effective therapy for schizophrenia

    High-quality randomized, double-blinded trials with sham controls and a systematic review do not demonstrate consistent benefit for hemodialysis in schizophrenia; overall evidence does not support hemodialysis as an effective therapy for this indication.

    • Multiple well-designed, sham-controlled clinical trials found no significant effect on schizophrenia symptoms (references summarized in chunk 6).

    Clinical Background & Evidence Summary

    Early uncontrolled reports from the late 1970s and early 1980s described symptom improvements in series of patients with schizophrenia after hemodialysis. However, these initial observations prompted randomized, double-blinded, sham-controlled trials that largely failed to replicate those findings. A systematic review (search through September 2018) identified 9 qualifying trials enrolling 105 patients; of those trials, one reported benefit, one reported harm, and six reported no effect. The review noted small study sizes, unclear or high risk of bias, and that adverse events occurred in 23% of patients. Overall, the later well-designed trials and the systematic review do not support hemodialysis as an effective treatment for schizophrenia.

    Definitions & Code Descriptions

    Hemodialysis (CPT codes)
    90935Hemodialysis procedure with single physician evaluation.
    90937Hemodialysis procedure requiring repeated evaluation(s) with or without substantial revision of dialysis prescription.
    Coverage noteThese CPT codes are listed in this policy as examples of hemodialysis procedure codes referenced for the indication of schizophrenia.
    Schizophrenia (ICD-10)
    F20.0 - F20.9Schizophrenia diagnoses (ICD-10 range representing schizophrenia).
    ContextThese ICD-10 codes are specified in the policy as the schizophrenia diagnoses referenced for exclusion of hemodialysis as a treatment for this indication.

    Policy Dates & History

    1998-10-13effective_date

    Policy effective date (document header).

    2023-05-05last_reviewLatest

    Most recent policy review date recorded in document header.

    2024-03-14next_review_scheduled

    Next scheduled policy review date recorded in document header.

    Policy Summary
    PayerAetna
    PolicyHemodialysis for Schizophrenia
    Policy CodePolicy 0291
    Change TypeNo material change
    Effective DateOct 13, 1998
    Last ReviewMay 5, 2023
    Next Review DateMar 14, 2024
    Key ActionDo not authorize hemodialysis for the treatment of schizophrenia because it is considered experimental and investigational.
    SourceLink
    On This Page
    Coverage DeterminationRelevant CodesProvider Billing & Documentation GuidanceClinical Background & Evidence SummaryDefinitions & Code DescriptionsPolicy Dates & History
  1. Systematic review identified 9 trials (105 patients) with mostly negative results and reported adverse events in 23% of patients (chunk 7).
  2. Documentation Required

    Documentation expectations if submitted — diagnosis codes and clinical rationale required

    If a claim for hemodialysis for schizophrenia is submitted, include the specific schizophrenia diagnosis codes and a clear clinical rationale; despite submission of documentation, the policy states the treatment is experimental and investigational based on lack of demonstrated effectiveness.

    • Include ICD-10 schizophrenia codes (F20.0–F20.9) on documentation and claims.
    • Provide clinical rationale explaining indication; note that lack of demonstrated efficacy in sham-controlled trials is the basis for the policy determination.
    Denial Risk

    Denial risk — hemodialysis for schizophrenia likely to be denied as experimental/investigational

    Claims for hemodialysis billed for the treatment of schizophrenia are at risk for denial because the therapy is considered experimental and investigational and Medicare does not cover it.

    • Policy: Hemodialysis for schizophrenia is considered experimental and investigational (chunk 3).
    • Medicare NCD states evidence is inconclusive and does not cover hemodialysis for treatment of schizophrenia (chunk 6).
    Related dialysis codesZ49.01 - Z49.32 (encounter for care involving renal dialysis); Z99.2 (dependence on renal dialysis) are listed separately in the coding section.